Compositions and methods for treating type ii diabetes and related disorders 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2011128782 A2 2011-10-20 [WO2011128782]WO2011128782 A3 2012-01-19 [WO2011128782]WO2011128782 A4 2012-03-15 [WO2011128782] / 2011-10-202012-01-192012-03-15
申请号/申请日
2011WO-IB01292 / 2011-04-13
发明人
ROSADO JORGE LUIS;DUARTE-VAZQUEZ MIGUEL ANGEL;
申请人
DUARTE-VAZQUEZ MIGUEL ANGEL;ROSADO JORGE LUIS;
主分类号
IPC分类号
A01N-033/02
摘要
(WO2011128782) The present invention relates to methods and compositions for treating type II diabetes.  This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas.  In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or rosiglitazone), at least one sulfonylurea (e.g., glimepiride), and at least one biguanide (e.g., metformin or a pharmaceutically acceptable salt or ester thereof, such as metformin HCl).  The present invention also provides methods of treating type II diabetes and related disorders in a mammal, suitably a human, by administering to a mammal in need thereof one or more of the compositions of the present invention.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2010US-61323788 2010-04-13
主权利要求
(WO2011128782) 1. WHAT IS CLAIMED IS: 1. A pharmaceutical composition suitable for oral administration for the treatment of diabetes and related disorders, comprising at least one insulin sensitizer, glimepinde, and metformin or pharmaceutically active salt or ester thereof. 2. The oral formulation according to claim 1, wherein the oral formulation is a solid formulation. 3. The oral formulation according to claim 2, wherein the solid formulation is selected from the group consisting of capsules, tablets, pills, powders, particles, and granules. 4. The oral formulation according to claim 1, wherein the oral formulation is a liquid formulation. 5. The oral formulation according to claim 4, wherein the liquid formulation is selected from the group consisting of emulsions, solutions, suspensions, syrups, and elixers. 6. The oral formulation according to claim 1 , wherein the oral formulation comprises from about 0.5 mg to about 40 mg of glimepiride. 7. The oral formulation according to claim 1, wherein the oral formulation comprises from about 2 mg to about 120 mg of said insulin sensitizer. 8. The oral formulation according to claim 1, wherein the oral formulation comprises from about 500 mg to about 5000 mg of metformin hydrochloride. 9. The oral formulation according to claim 1 , wherein the oral formulation comprises sustained-release or extended-release metformin hydrochloride. 10. The oral formulation according to claim 1, wherein the insulin sensitizer is a glitazone. 1 1. The oral formulation of claim 10, wherein said glitazone is pioglitazone. 12. The oral formulation according to claim 10, wherein said glitazone is rosiglitazone. 13. The oral formulation according to claim 1, wherein said formulation comprises about 2 mg to about 120 mg of an insulin sensitizer selected from the group consisting of pioglitazone and rosiglitazone, about 0.5 mg to about 40 mg glimepiride, and about 500 mg to about 5000 mg metformin hydrochloride. 14. A kit for use in treating Type II diabetes, comprising the oral formulation of claim 1 and a label containing instructions to administer the oral formulation once per day, twice per day, three times per day, or four times per day to a subject in need thereof. 15. A method for treating diabetes and related disorders in a mammal, comprising administering to said mammal an oral formulation comprising at least one insulin sensitizer, glimepiride, and metformin or pharmaceutically active salt or ester thereof. 16. The method according to claim 15, wherein said mammal is human. 17. The method according to claim 15, wherein the method comprises administering to said mammal a daily dose of glimepiride of about 0.5 mg to about 40 mg. 18. The method according to claim 15, wherein the method comprises administering to said mammal a daily dose of said insulin sensitizer of about 2 mg to about 120 mg. 19. The method according to claim 15, wherein the method comprises administering to said mammal a daily dose of metformin, or pharmaceutically active salt or ester thereof, of about 500 mg to about 5000 mg. 20. The method according to claim 15, wherein the oral formulation comprises sustained-release or extended-release metformin hydrochloride. 21. The method according to claim 15, wherein the insulin sensitizer is a glitazone. 22. The method according to claim 21, wherein said glitazone is pioglitazone. 23. The method according to claim 21, wherein said glitazone is rosiglitazone. 24. The method according to claim 15, wherein said metformin or pharmaceutically active salt or ester thereof is metformin HC1. 25. A method for treating diabetes and related disorders in a mammal, comprising administering to said mammal an oral formulation comprising pioglitazone, glimepiride, and metformin HC1. 26. The method of claim 25, wherein said pioglitazone is present in said oral formulation in an amount of about 2 mg to about 120 mg. 27. The method of claim 26, wherein said pioglitazone is present in said oral formulation in an amount of about 15 mg. 28. The method of claim 25, wherein said glimepiride is present in said oral formulation in an amount of about 0.5 mg to about 40 mg. 29. The method of claim 28, wherein said glimepiride is present in said oral formulation in an amount of about 2 mg. 30. The method of claim 25, wherein said metformin HCl is present in said oral formulation in an amount of about 500 mg to about 5000 mg. 31. The method of claim 25, wherein said metformin HCl is present in said oral formulation in an amount of about 500 mg to about 850 mg. 32. The method of claim 25, wherein said metformin HCl is present in said oral formulation in an amount of about 500 mg. 33. The method of claim 25, wherein said metformin HCl is present in said oral formulation in an amount of about 850 mg. 34. The method of claim 25, wherein the oral formulation comprises sustained-release or extended-release metformin hydrochloride. 35. The method of claim 25, wherein said mammal is a human. 36. A method for treating diabetes and related disorders in a mammal, comprising administering to said mammal the pharmaceutical formulation of claim 1. 37. The method of claim 36, wherein said mammal is a human.
法律状态
(WO2011128782) LEGAL DETAILS FOR WO2011128782  Actual or expected expiration date=2013-10-13    Legal state=DEAD    Status=LAPSED     Event publication date=2011-04-13  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOIB2011001292  Application date=2011-04-13  Standardized application number=2011WO-IB01292     Event publication date=2011-10-20  Event code=WO/A2  Event type=Examination events  International application published with declaration under Article 17 (2) (a)  Publication country=WO  Publication number=WO2011128782  Publication stage Code=A2  Publication date=2011-10-20  Standardized publication number=WO2011128782     Event publication date=2012-01-19  Event code=WO/A3  Event indicator=Pos  Event type=Examination events  Later publication of ISR with revised front page  Publication country=WO  Publication number=WO2011128782  Publication stage Code=A3  Publication date=2012-01-19  Standardized publication number=WO2011128782     Event publication date=2012-03-15  Event code=WO/A4  Event indicator=Pos  Event type=Examination events  Published application with amended claims  Publication country=WO  Publication number=WO2011128782  Publication stage Code=A4  Publication date=2012-03-15  Standardized publication number=WO2011128782     Event publication date=2013-10-13  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE BR112012026005  Actual or expected expiration date=2015-12-08    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=BR Corresponding appl: BR112012026005  Application date in the designated or member state=2011-04-13   Application number in the designated or member state=2012BR-0026005 Corresponding cc:  Designated or member state=BR Corresponding pat: BR112012026005  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2013-07-02   Publication number in the designated or member state=BR112012026005    Event publication date=2013-07-02  Event code=WO/REG  Event code=BR/B01A  Event type=Examination events  Reference to a national code Pct publication - request for entry into the national phase Comunicacao da publicacao internacional pct. apresentacao de peticao de requerimento de entrada na fase nacional Corresponding cc:  Designated or member state=BR     Event publication date=2015-09-08  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=BR   Effective date of the event=2012-10-10     Event publication date=2016-04-05  Event code=BR/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=BR  LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2012-10-15    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2012-10-15  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE MX2012005998  Actual or expected expiration date=2031-04-13    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=MX Corresponding appl: MX2012005998  Application date in the designated or member state=2011-04-13   Application number in the designated or member state=2012MX-PA05998 Corresponding cc:  Designated or member state=MX Corresponding pat: MX2012005998  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2013-06-18   Publication number in the designated or member state=MX2012005998
专利类型码
A2A3A4
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部